awmsg logo



eslicarbazepine acetate (Zebinix®)


Reference No. 1214

Publication date:
26/06/2019


Appraisal information

eslicarbazepine acetate (Zebinix®) 800 mg tablet
eslicarbazepine acetate (Zebinix®) 200 mg tablet
eslicarbazepine acetate (Zebinix®) 50 mg/ml oral suspension


Company: Eisai Ltd
BNF category: Central nervous system
NMG meeting date: 08/05/2019
AWMSG meeting date: 19/06/2019
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 1019
Ratification by Welsh Government: 25/06/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Eslicarbazepine acetate (Zebinix®) is recommended as an option for restricted use within NHS Wales. Eslicarbazepine acetate (Zebinix®) should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations, within its licensed indication as adjunctive therapy in adults, adolescents and children aged above six years, with partial onset seizures, with or without secondary generalisation. Eslicarbazepine acetate (Zebinix®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download